ORGO News & Events

The post-Christmas session saw stocks fluctuate near all-time highs and the indexes close little changed following a day of thin trading. While the S&P 500 saw a very small daily drop, it still closed with its best week in a month.Get caught up quickly on the top news and calls moving stocks with this recap from The Fly.1. STOCK NEWS:Nvidialicensingand hiring top executives, including its CEO, in deal reported to be worth $20BTargetfacing pressure from activist investor Toms Capital,Biohavenannounced on Christmas Eve that its Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorderWALL STREET CALLS:Inhibikase Therapeuticswith a Buy at H.C. WainwrightCarter Bankshareswith a Buy at Freedom CapitalMDU Resourceswith a Hold at Freedom CapitalWalmartwith an Outperform at CICC3. AROUND THE WEB:Following the Trump administration's approval of a weapons sale to Taiwan, the Chinese government imposed sanctions on 20 U.S. defense companies and 10 of their executives, with targets including Northrop Grumman (NOC), Boeing'sdefense unit,A federal judge denied Masimo'srequest to block Apple Watchimports as part of its lawsuit over an earlier import ban related to patents covering blood-oxygen sensors,Hyattis developing collaborations with Chinese state-owned companies for joint-venture brands amid a slowdown in the region and an effort to expand outside Greater China to double properties in Asia,JPMorgan Chasein recent months has frozen accounts used by at least two fast-growing stablecoin startups, highlighting the risk that Cryptocurrency transactions pose for banks, which are required to know the people they do business with and the source of their cash,4. MOVERS:Coupanggained afterthe company identified the former employee responsible for the recent data leakNikerose after UBS said its recentfor the companyArcadia Biosciencesfell afterand resumption of its process of evaluating strategic alternativesMakers of wound-care products, including Organogenesis, declined after regional Medicare contractorsand tissue repair productsINDEXES:The Dow fell 0.04%, or 20.19, to 48,710.97, the Nasdaq slipped 0.09%, or 20.21, to 23,593.10, and the S&P 500 declined 0.03%, or 2.11, to 6,929.94.

Shares of makers of wound-care products, including MidMedxand Organogenesis, are under pressure on Friday after the Centers for Medicare & Medicaid Services said in a press release that the Medicare Administrative Contractors are withdrawing the skin substitute Local Coverage Determinations, which were due to become effective on January 1, 2026. Craig-Hallum believes this will likely drive some level of disappointment from investors as the LCDs were considered a positive for MidMedx. Meanwhile, BTIG said the firm is more cautious on Organogenesis after CMS ruling on skin grafts, with its confidence on the stock as 2026 Top Pick now being reduced.BOMBSHELL FROM CMS:Craig-Hallum notes that After market close on December 24, the Centers for Medicare & Medicaid Services released "a bombshell" in the form of a very laconic press release announcing that the Medicare Administrative Contractors are withdrawing the skin substitute Local Coverage Determinations, which were due to become effective on January 1, 2026. Without further explanation given in the press release, investors will be wondering what is going on here, the firm argues, adding that this move is particularly surprising considering CMS released a press release just last week essentially confirming that the LCDs would be going into effect. This will likely drive some level of disappointment from investors as the LCDs were considered a positive for MidMedx, Craig-Hallum adds. The firm has a Buy rating on the shares with a price target of $13.MORE CAUTIOUS:BTIG keeps a Buy rating and $9 price target on Organogenesis but notes that the firm's confidence on the stock as 2026 Top Pick is being reduced. BTIG cites CMS announcing that it would not implement the final Skin-Sub LCDs on January 1, 2026, noting that this unexpected update comes just 9 days after CMS announced that the MACs would be implementing the LCDs but with products classified into 3 categories - covered, non-covered, and 12-month status quo - even though the firm still believes that low-cost providers such as Organogenesis will be best-positioned in the market, the firm tells investors in a research note.PRICE ACTION:Shares of MiMedx have slipped more than 3% to $6.84 on Friday, while Organogenesis' stock has fallen almost 10% to $5.30.